Myocardial Infarction (MI) Triad Test Panel

Myo/CK-MB/cTnI Rapid Testing Kits – Introduction

This Myocardial Infarction test is for simultaneous qualitative determination of myoglobin (Myo), creatine kinase MB (CK-MB), and cardiac troponin I (cTnI) in human plasma or serum. MI triad test results are used as an aid in the diagnosis of acute myocardial infarction in emergency room, critical care, point-of-care and hospital settings. MI rapid test panel provides a qualitative analytical test result. This Myo/CK-MB/cTnI qualitative nature of this assay does not provide information about any change – either the rise or fall – in the concentration of myoglobin, CK-MB, or cardiac troponin I (cTnI) with a single test. With this MI serum test, the detection of these three markers is complementary in diagnosis of myocardial infarction since they detect cardiac tissue damage at different time structure and over a wide range of times after myocardial infarction. So the accuracy of the diagnosis will be higher than a single CK-MB test, Myoglobin test or a cTnI test.

MI 3-in-1 Immunoassay Testing Principle

Myo/CK-MB/cTnI mycardial infarction (MI) 3-in-1 test panel uses a solid-phase chromatographic immunoassay technology to qualitatively detect the elevation of myoglobin (Myo), CK-MB, and troponin I (cTnI) in human serum or plasma samples. When serum or plasma sample is added to the sample wells, it will move along the three independent membrane strips. Myo, CK-MB and cTnI in the sample, if any, will be bound to specific antibody-dye conjugates and move to the test regions (T) where immobilized anti-myoglobin, anti-CK-MB, and streptavidin have been pre-coated respectively. The cardiac marker-antibody-dye complexes will bind to the corresponding immobilized antibodies or streptavidin in the test regions. Red lines will appear, indicating a positive result. Unbound dye complexes move on to the control region (C) and will be captured there. The red line in the control region provides a internal control mechanism.

The Myoglobin/CK-MB/Troponin I Combo Rapid Test Device (Whole Blood/Serum/Plasma)
provides performance equivalent to the market leader at a fraction of the cost. Troponin I –
Sensitivity: 98.7%, Specificity: 98.4%
Myoglobin – Sensitivity: >99.9%, Specificity: 97.7%
CK-MB – Sensitivity: >99.9%, Specificity: 99.8%